Salazar N P, Saniel M C, Estoque M H, Talao F A, Bustos D G, Palogan L P, Gabriel A I
Research Institute for Tropical Medicine, Department of Health, Alabang, Muntinlupa, Metro Manila, Philippines.
Southeast Asian J Trop Med Public Health. 1990 Sep;21(3):397-403.
Clinical trials on oral clindamycin as an antimalarial in hospitalized patients and residents of endemic communities were conducted in the Philippines between May 1984 and December 1985. Seven and 9 qualified subjects in hospital were treated with 300 mg (regimen A) and 600 mg (regimen B) respectively, twice daily for 5 days. Eighteen patients seen at a rural health unit were given the lower dosage. On the basis of the 28-day extended in vivo test of WHO, P. falciparum in all but one patient showed susceptibility to the drug as a blood schizontocide hence, the clinical cure of malaria. Side effects were few and self-limiting. Ten other patients on regimen A were cured within the 7- and/or 28-day extended test period. Clindamycin per se is currently one of the few alternatives in the treatment of clinically moderate drug-resistant malaria.
1984年5月至1985年12月期间，在菲律宾对住院患者和疟疾流行社区居民开展了口服克林霉素作为抗疟药的临床试验。医院里分别有7名和9名合格受试者接受治疗，方案A为每日两次，每次300毫克，方案B为每日两次，每次600毫克，持续5天。在一个农村卫生单位就诊的18名患者接受了较低剂量治疗。根据世卫组织28天延长体内试验，除一名患者外，所有患者体内的恶性疟原虫对该药物作为血内裂殖体杀灭剂均敏感，因此实现了疟疾的临床治愈。副作用较少且具有自限性。在7天和/或28天延长试验期内，方案A的其他10名患者也被治愈。克林霉素本身目前是治疗临床中度耐药疟疾的少数替代药物之一。
